Lupus trials recruiting in New York

All Lupus trials nationally

Cities in New York

Recruiting trials in New York

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
  NCT07260877 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: Fairport
• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
  NCT06308978 · Phase: Phase 1 · Ages: 12 Years to 70 Years · Sex: All (male and female) · New York: New York
• A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
  NCT06557265 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York, Stony Brook, Syracuse
• A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
  NCT06625671 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: Syracuse
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: Great Neck, Hawthorne, New York, Rochester
• A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
  NCT07328581 · Phase: Phase 2 · Ages: 16 Years to 70 Years · Sex: All (male and female) · New York: Hawthorne, New Hyde Park
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · New York: Brooklyn
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · New York: Brooklyn
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
  NCT06613360 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: New York, Rochester
• A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
  NCT06875960 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female) · New York: Brooklyn, Manhasset, New York, Syracuse
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
  NCT05039619 · Phase: Phase 2 · Ages: 5 Years to 17 Years · Sex: All (male and female) · New York: Queens
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
  NCT07085104 · Phase: Phase 1 · Ages: 18 Years to 74 Years · Sex: All (male and female) · New York: New York
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
  NCT06897930 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: New York, Syracuse
• Alnuctamab for Refractory SLE (LATTE Study)
  NCT07219563 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · New York: New York
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · New York: New Hyde Park, New York, The Bronx, Valhalla
• Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
  NCT05799378 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · New York: New York, The Bronx
• HEALTH Home Urinalysis Testing
  NCT07823478 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
  NCT03152058 · Phase: Phase 2 · Ages: 18 Years to 40 Years · Sex: Female · New York: New York
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
  NCT07138898 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Lupus Landmark Study: A Prospective Registry and Biorepository
  NCT05934149 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · New York: Manhasset, New York, Syracuse
• Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
  NCT07053800 · Phase: Phase 2 · Ages: 12 Years to 65 Years · Sex: All (male and female) · New York: New York, Syracuse
• PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
  NCT07611214 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: Orchard Park
• Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
  NCT06711887 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · New York: Orchard Park
• Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
  NCT00198068 · Phase: Not specified · Ages: 18 Years to 45 Years · Sex: Female · New York: New York
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
  NCT06121297 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York, Rochester
• Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
  NCT01802034 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Safety and Efficacy of ONT01 in Lupus
  NCT07107659 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Safety of the Herpes Zoster Subunit Vaccine in Lupus
  NCT05559671 · Phase: Phase 4 · Ages: 18 Years to 90 Years · Sex: All (male and female) · New York: New York
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
  NCT05268289 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · New York: East Setauket
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York
• The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
  NCT05538208 · Phase: Phase 2 · Ages: 8 Years to 20 Years · Sex: All (male and female) · New York: New York
• Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
  NCT06232304 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 22 Years · Sex: All (male and female) · New York: The Bronx
• Trial of Belimumab in Early Lupus
  NCT03543839 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · New York: Manhasset
• VIBRANT: VIB4920 for Active Lupus Nephritis
  NCT05201469 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Manhasset, New York